Cargando…

NFE2L3 as a Novel Biomarker Associated With IL-2/STAT5/NLRP3 Signaling Pathway in Malignant Pleural Mesothelioma and Other Cancers

Background: Malignant pleural mesothelioma (MPM) is a malignant tumor originating from pleural mesothelial cells and has a high mortality rate worldwide. With the advent of immunotherapy in MPM treatment, there is an urgent need to elucidate the immune-related mechanisms in this caner. Methods: Sing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhen, Yang, Han, Luo, Bin, Duan, Pengfei, Lin, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Genetics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158472/ https://www.ncbi.nlm.nih.gov/pubmed/35664314 http://dx.doi.org/10.3389/fgene.2022.805256

Ejemplares similares

Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma
por: Kresoja-Rakic, Jelena, et al.
Publicado: (2017)

Multi-Omics Analysis of Molecular Characteristics and Carcinogenic Effect of NFE2L3 in Pan-Cancer
por: Liu, Mengxiao, et al.
Publicado: (2022)

Identification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients
por: Bai, Yiyang, et al.
Publicado: (2020)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Circulating biomarkers in malignant pleural mesothelioma
por: Viscardi, Giuseppe, et al.
Publicado: (2020)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma
por: Mezzapelle, R, et al.
Publicado: (2013)

NFE2L2 and STAT3 Converge on Common Targets to Promote Survival of Primary Lymphoma Cells
por: Arena, Andrea, et al.
Publicado: (2023)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Modern management of malignant pleural mesothelioma
por: Patel, Shivani C, et al.
Publicado: (2016)

Pleural tuberculosis mimicking malignant mesothelioma
por: Dawood, Wajahat, et al.
Publicado: (2019)

Cytomegalovirus infection in malignant pleural mesothelioma
por: Hunter-Schlichting, DeVon, et al.
Publicado: (2021)

Immunotherapeutic Approaches in Malignant Pleural Mesothelioma
por: Terenziani, Rita, et al.
Publicado: (2021)

Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021)

KRAS signaling in malignant pleural mesothelioma
por: Marazioti, Antonia, et al.
Publicado: (2021)

ECM Mechanoregulation in Malignant Pleural Mesothelioma
por: Panzetta, Valeria, et al.
Publicado: (2022)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
por: Al Khatib, MHD Ouis, et al.
Publicado: (2023)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2020)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma
por: Kim, Min-Kyu, et al.
Publicado: (2020)

Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models
por: Barbone, Dario, et al.
Publicado: (2015)

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2016)

Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma
por: Meirson, Tomer, et al.
Publicado: (2022)

An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma
por: Linton, A, et al.
Publicado: (2014)

Cerebral metastasis from malignant pleural mesothelioma
por: El Molla, Mohamed, et al.
Publicado: (2013)

Localized malignant pleural mesothelioma with renal metastasis
por: Zardawi, Sarah Jane, et al.
Publicado: (2015)

Chondrosarcoma of the Rib Mimicking Malignant Pleural Mesothelioma
por: Furukawa, Masashi, et al.
Publicado: (2016)

CD7 Expression in Malignant Pleural Mesothelioma
por: Hibi, Shigeyoshi, et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_s5fuufeb6kt4bsqg2raald0rt9